Utilization of antiproliferative and antimigratory compounds for the prevention of restenosis

Textbook of Interventional Cardiovascular Pharmacology

Volumn , Issue , 2007, Pages 299-313

  Kamath, Kalpana R ^a   Barry, James J ^b  

^a BOSTON SCIENTIFIC CORPORATION   (United States)

^b BAPTIST CARDIAC AND VASCULAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79952686995     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (106)

1. Investigators TBARIB. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N Engl J Med 1996; 335(4):217-225.
2. Serruys PW, Unger F, Sousa JE, et al. Comparison of coronaryartery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001; 344(15):1117-1124.
3. Wiskirchen J, Schober W, Schart N, et al. The effects of paclitaxel on the three phases of restenosis: smooth muscle cell proliferation, migration, and matrix formation: an in vitro study. Invest Radiol 2004; 39(9):565-571.
4. Hiatt BL, Ikeno F, Yeung AC, Carter AJ. Drug-eluting stents for the prevention of restenosis: in quest for the Holy Grail. Catheter Cardiovasc Interv 2002; 55(3):409-417.
5. Farb A, Sangiorgi G, Carter AJ, et al. Pathology of acute and chronic coronary stenting in humans. Circulation 1999; 99(1):44-52.
6. Farb A, Weber DK, Kolodgie FD, Burke AP, Virmani R. Morphological predictors of restenosis after coronary stenting in humans. Circulation 2002; 105(25):2974-2980.
7. Hoffmann R, Mintz GS, Dussaillant GR, et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation 1996; 94(6):1247-1254.
8. Virmani R, Farb A. Pathology of in-stent restenosis. Curr Opin Lipidol 1999; 10(6):499-506.
9. Wahlgren CM, Frebelius S, Swedenborg J. Inhibition of neo- intimal hyperplasia by a specific thrombin inhibitor. Scand Cardiovasc J 2004; 38(1):16-21.
10. Costa MA, Simon DI. Molecular basis of restenosis and drugeluting stents. Circulation 2005; 111(17):2257-2273.
11. Welt FG, Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol 2002; 22(11):1769-1776.
12. Chesebro JH, Lam JY, Badimon L, Fuster V. Restenosis after arterial angioplasty: a hemorrheologic response to injury. Am J Cardiol 1987; 60(3):10B-16B.
13. Ferns GA, Raines EW, Sprugel KH, Motani AS, Reidy MA, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 1991; 253(5024):1129-1132.
14. Ip JH, Fuster V, Israel D, Badimon L, Badimon J, Chesebro JH. The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty. J Am Coll Cardiol 1991; 17(6 suppl B):77B-88B.
15. Willerson JT, Yao SK, McNatt J, et al. Frequency and severity of cyclic flow alternations and platelet aggregation predict the severity of neointimal proliferation following experimental coronary stenosis and endothelial injury. Proc Natl Acad Sci USA 1991; 88(23):10624-10628.
16. Kamath KR, Barry JJ, Miller KM. The Taxus drug-eluting stent: a new paradigm in controlled drug delivery. Adv Drug Deliv Rev 2006; 58(3):412-436.
17. Lau K-W, Sigwart U. Restenosis-an accelerated arteriopathy: pathophysiology, preventive strategies and research horizons. In: Edelman ER, Levy RJ, eds. Molecular Interventions and Local Drug Delivery. London: W. B. Saunders Co. Ltd, 1995:I-28.
18. Chorny M, Fishbein I, Golomb G. Drug delivery systems for the treatment of restenosis. Crit Rev Ther Drug Carrier Syst 2000; 17(3):249-284.
19. Lincoff AM, Topol EJ, Ellis SG. Local drug delivery for the prevention of restenosis. Fact, fancy, and future. Circulation 1994; 90(4):2070-2084.
20. Kavanagh CA, Rochev YA, Gallagher WM, Dawson KA, Keenan AK. Local drug delivery in restenosis injury: thermo- responsive co-polymers as potential drug delivery systems. Pharmacol Ther 2004; 102(1):1-15.
21. Bailey SR. Local drug delivery: current applications. Prog Cardiovasc Dis 1997; 40(2):183-204.
22. Camenzind E, Kint PP, Di Mario C, et al. Intracoronary heparin delivery in humans. Acute feasibility and long-term results. Circulation 1995; 92(9):2463-2472.
23. Mitchel JF, McKay RG. Treatment of acute stent thrombosis with local urokinase therapy using catheter-based, drug delivery systems: a case report. Cathet Cardiovasc Diagn 1995; 34(2):149-54.
24. Tahlil O, Brami M, Feldman LJ, Branellec D, Steg PG. The Dispatch catheter as a delivery tool for arterial gene transfer. Cardiovasc Res 1997; 33(1):181-187.
25. Bailey SR. Coronary restenosis: a review of current insights and therapies. Catheter Cardiovasc Interv 2002; 55(2):265-271.
26. Lambert CR, Leone JE, Rowland SM. Local drug delivery catheters: functional comparison of porous and microporous designs. Coron Artery Dis 1993; 4(5):469-475.
27. Hanke H, Strohschneider T, Oberhoff M, Betz E, Karsch KR. Time course of smooth muscle cell proliferation in the intima and media of arteries following experimental angioplasty. Circ Res 1990; 67(3):651-659.
28. Holmes DR Jr, Simpson JB, Berdan LG, et al. Abrupt closure: the CAVEAT I experience. Coronary angioplasty versus excisional atherectomy trial. J Am Coll Cardiol 1995; 26(6): 1494-1500.
29. Linde J, Strauss BH. Pharmacological treatment for prevention of restenosis. Expert Opin Emerg Drugs 2001; 6(2): 281-302.
30. Rogers C, Edelman ER, Simon DI. A mAb to the beta2-leuko- cyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits. Proc Natl Acad Sci U S A 1998; 95(17):10134-10139.
31. Simon DI, Dhen Z, Seifert P, Edelman ER, Ballantyne CM, Rogers C. Decreased neointimal formation in Mac-1(-/ -) mice reveals a role for inflammation in vascular repair after angioplasty. J Clin Invest 2000; 105(3):293-300.
32. Fidler J. Clinical Oncology. New York: Churchill Livingstone, 2000.
33. Li JJ, Gao RL. Should atherosclerosis be considered a cancerof the vascular wall? Med Hypotheses 2005; 64(4):694-698.
34. Serruys PW, Ormiston JA, Sianos G, et al. Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trial. J Am Coll Cardiol 2004; 44(7):1363-1367.
35. Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 1995; 76(3):412-417.
36. Bruns CJ, Koehl GE, Guba M, et al. Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer. Clin Cancer Res 2004; 10(6):2109-2119.
37. Adams JD, Flora KP, Goldspiel BR, Wilson JW, Arbuck SG, Finley R. Taxol: a history of pharmaceutical development and current pharmaceutical concerns. J Natl Cancer Inst Monogr 1993; 15:141-147.
38. Ramaswamy B, Puhalla S. Docetaxel: a tubulin-stabilizing agent approved for the management of several solid tumors. Drugs Today (Barc) 2006; 42(4):265-279.
39. Mullins DW, Koci MD, Burger CJ, Elgert KD. Interleukin-12 overcomes paclitaxel-mediated suppression of T-cell proliferation. Immunopharmacol Immunotoxicol 1998; 20(4):473-492.
40. Tange S, Scherer MN, Graeb C, et al. The antineoplastic drug paclitaxel has immunosuppressive properties that can effectively promote allograft survival in a rat heart transplant model. Transplantation 2002; 73(2):216-223.
41. Hui A, Min WX, Tang J, Cruz TF. Inhibition of activator protein 1 activity by paclitaxel suppresses interleukin-1-induced collagenase and stromelysin expression by bovine chondrocytes. Arthritis Rheum 1998; 41(5):869-876.
42. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995; 332(15):1004-1014.
43. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979; 277(5698):665-667.
44. Jordan MA, Thrower D, Wilson L. Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res 1991; 51(8):2212-2222.
45. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A 1980; 77(3):1561-1565.
46. Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci U S A 1993; 90(20):9552-9556.
47. Sollott SJ, Cheng L, Pauly RR, et al. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J Clin Invest 1995; 95(4):1869-1876.
48. Ganansia-Leymarie V, Bischoff P, Bergerat JP, Holl V. Signal transduction pathways of taxanes-induced apoptosis. Curr Med Chem Anti-canc Agents 2003; 3(4):291-306.
49. Blagosklonny MV, Darzynkiewicz Z, Halicka HD, et al. Paclitaxel induces primary and postmitotic G1 arrest in human arterial smooth muscle cells. Cell Cycle 2004; 3(8):1050-1056.
50. Giannakakou P, Robey R, Fojo T, Blagosklonny MV. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity. Oncogene 2001; 20(29):3806-3813.
51. Axel DI, Kunert W, Goggelmann C, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997; 96(2):636-645.
52. Blagosklonny MV, Demidenko ZN, Giovino M, et al. Cytostatic activity of paclitaxel in coronary artery smooth muscle cells is mediated through transient mitotic arrest followed by permanent post-mitotic arrest: comparison with cancer cells. Cell Cycle 2006; 5(14):1574-1579.
53. Oberhoff M, Herdeg C, Al Ghobainy R, et al. Local delivery of paclitaxel using the double-balloon perfusion catheter before stenting in the porcine coronary artery. Catheter Cardiovasc Interv 2001; 53(4):562-568.
54. Celletti FL, Waugh JM, Amabile PG, Kao EY, Boroumand S, Dake MD. Inhibition of vascular endothelial growth factor- mediated neointima progression with angiostatin or paclitaxel. J Vasc Interv Radiol 2002; 13(7):703-707.
55. Patterson C, Mapera S, Li HH, et al. Comparative effects of paclitaxel and rapamycin on smooth muscle migration and survival. Role of Akt-dependent signaling. Arterioscler Thromb Vasc Biol 2006; 26(7):1479-1480.
56. Drachman DE, Edelman ER, Seifert P, et al. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J Am Coll Cardiol 2000; 36(7):2325-2332.
57. Heldman AW, Cheng L, Jenkins GM, et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 2001; 103(18):2289-2295.
58. Hou D, Rogers PI, Toleikis PM, Hunter W, March KL. Intrapericardial paclitaxel delivery inhibits neointimal proliferation and promotes arterial enlargement after porcine coronary overstretch. Circulation 2000; 102(13):1575-1581.
59. Kolodgie FD, John M, Khurana C, et al. Sustained reduction of in-stent neointimal growth with the use of a novel systemic nanoparticle paclitaxel. Circulation 2002; 106(10):1195-1198.
60. Signore PE, Machan LS, Jackson JK, et al. Complete inhibition of intimal hyperplasia by perivascular delivery of paclitaxel in balloon-injured rat carotid arteries. J Vasc Interv Radiol 2001; 12(1):79-88.
61. Farb A, Heller PF, Shroff S, et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 2001; 104(4):473-479.
62. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004a; 350(3):221-231.
63. Stone G, Ellis S, Cox D, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004b; 109(16):1942-1947.
64. Grube E, Lansky A, Hauptmann KE, et al. High-dose 7- hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization: one-year results from the SCORE randomized trial. J Am Coll Cardiol 2004; 44(7):1368-1372.
65. Gershlick A, De Scheerder I, Chevalier B, et al. Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. Circulation 2004; 109(4):487-493.
66. Hong MK, Mintz GS, Lee CW, et al. Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries: a serial volumetric intravascular ultrasound analysis from the Asian Paclitaxel-Eluting Stent Clinical Trial (ASPECT). Circulation 2003; 107(4):517-520.
67. Silber S. Paclitaxel-eluting stents: are they all equal? An analysis of six randomized controlled trials in de novo lesions of 3,319 patients. J Interv Cardiol 2003; 16(6):485-490.
68. Grube E, Silber S, Hauptmann KE, et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003; 107(1):38-42.
69. Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003; 108(7):788-794.
70. Tanabe K, Serruys PW, Grube E, et al. TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 2003; 107(4):559-564.
71. Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 2005; 294(10):1215-1223.
72. Abizaid A, Chan C, Lim Y-T, et al. Twelve-month outcomes with a paclitaxel-eluting stent transitioning from controlled trials to clinical practice: the WISDOM registry. Am J Cardiol 2006; 98:1028-1032.
73. ® paclitaxel-eluting stent clinical trial program. J Interv Cardiol 2006; 19:422-431.
74. Saia F, Lemos PA, Hoye A, et al. Clinical outcomes for sirolimus-eluting stent implantation and vascular brachytherapy for the treatment of in-stent restenosis. Catheter Cardiovasc Interv 2004; 62(3):283-288.
75. Tanabe K, Serruys PW, Degertekin M, et al. Chronic arterial responses to polymer-controlled paclitaxel-eluting stents: comparison with bare metal stents by serial intravascular ultrasound analyses: data from the randomized TAXUS-II trial. Circulation 2004; 109(2):196-200.
76. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: drug-eluting stents: Part II. Circulation 2003; 107(18): 2383-2389.
77. Whitworth HB, Roubin GS, Hollman J, et al. Effect of nifedipine on recurrent stenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1986; 8(6): 1271-1276.
78. Corcos T, David PR, Val PG, et al. Failure of diltiazem to prevent restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 1985; 109(5 Pt I):926-931.
79. Hoberg E, Dietz R, Frees U, et al. Verapamil treatment after coronary angioplasty in patients at high risk of recurrent stenosis. Br Heart J 1994; 71(3):254-260.
80. Schwartz L, Bourassa MG, Lesperance J, et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988; 318(26):1714-1719.
81. Bertrand ME, Allain H, Lablanche JM. Results of a randomized trial of ticlopidine vs placebo for prevention of acute closure and restenosis after coronary angioplasty. The TACT study. Circulation 1990; 82(suppl 3):190.
82. Okamoto S, Inden M, Setsuda M, Konishi T, Nakano T. Effects of trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, in preventing restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 1992; 123(6): 1439-1444.
83. Serruys PW, Rutsch W, Heyndrickx GR, et al. Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2-receptor blockade. A randomized, double-blind, placebo-controlled trial. Coronary Artery Restenosis Prevention on Repeated Thromboxane-Antagonism Study (CARPORT). Circulation 1991; 84(4):1568-1580.
84. Knudtson ML, Flintoft VF, Roth DL, Hansen JL, Duff HJ. Effect of short-term prostacyclin administration on restenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1990; 15(3):691-697.
85. Urban P, Buller N, Fox K, Shapiro L, Bayliss J, Rickards A. Lack of effect of warfarin on the restenosis rate or on clinical outcome after balloon coronary angioplasty. Br Heart J 1988; 60(6):485-488.
86. Ellis SG, Roubin GS, Wilentz J, Douglas JS Jr, King SB III. Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. Am Heart J 1989; 117(4):777-782.
87. Stone GW, Rutherford BD, McConahay DR, et al. A randomized trial of corticosteroids for the prevention of restenosis in 102 patients undergoing repeat coronary angioplasty. Cathet Cardiovasc Diagn 1989; 18(4):227-231.
88. Pepine CJ, Hirshfeld JW, Macdonald RG, et al. A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty. M-HEART Group. Circulation 1990; 81(6): 1753-1761.
89. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Circulation 1992; 86(1):100-110.
90. Desmet W, Vrolix M, De Scheerder I, Van Lierde J, Willems JL, Piessens J. Angiotensin-converting enzyme inhibition with fosinopril sodium in the prevention of restenosis after coronary angioplasty. Circulation 1994; 89(1):385-392.
91. O'Keefe JH Jr, McCallister BD, Bateman TM, Kuhnlein DL, Ligon RW, Hartzler GO. Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty. J Am Coll Cardiol 1992; 19(7):1597-1600.
92. Kent KN, Williams DO, Cassagneau B, et al. Double-blind, controlled trial of the effect of angiopeptin on coronary restenosis following coronary angioplasty. Circulation 1993; 88(suppl 1):5063.
93. Eriksen UH, Amtorp O, Bagger JP, et al. Continuous angiopeptin infusion reduces coronary restenosis following balloon angioplasty. Circulation 1993; 88(suppl 1):594.
94. Serruys PW, Klein W, Tijssen JP, et al. Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. A multicenter randomized double-blind placebo-controlled trial. Circulation 1993; 88(4 Pt 1): 1588-1601.
95. Sahni R, Maniet AR, Voci G, Banka VS. Prevention of restenosis by lovastatin after successful coronary angioplasty. Am Heart J 1991; 121(6 Pt 1):1600-1608.
96. Bairati I, Roy L, Meyer F. Double-blind, randomized, controlled trial of fish oil supplements in prevention of recurrence of stenosis after coronary angioplasty. Circulation 1992; 85(3):950-956.
97. Dehmer GJ, Popma JJ, van den Berg EK, et al. Reduction in the rate of early restenosis after coronary angioplasty by a diet supplemented with n-3 fatty acids. N Engl J Med 1988; 319(12):733-740.
98. Grigg LE, Kay TW, Valentine PA, et al. Determinants of restenosis and lack of effect of dietary supplementation with eicosapentaenoic acid on the incidence of coronary artery restenosis after angioplasty. J Am Coll Cardiol 1989; 13(3):665-672.
99. Nye ER, Ablett MB, Robertson MC, Ilsley CD, Sutherland WH. Effect of eicosapentaenoic acid on restenosis rate, clinical course and blood lipids in patients after percutaneous transluminal coronary angioplasty. Aust N Z J Med 1990; 20(4):549-552.
100. Reis GJ, Boucher TM, Sipperly ME, et al. Randomised trial of fish oil for prevention of restenosis after coronary angioplasty. Lancet 1989; 2(8656):177-181.
101. Muller DW, Topol EJ, Abrams GD, Gallagher KP, Ellis SG. Intramural methotrexate therapy for the prevention of neointimal thickening after balloon angioplasty. J Am Coll Cardiol 1992; 20(2):460-466.
102. Gradus-Pizlo I, Wilensky RL, March KL, et al. Local delivery of biodegradable microparticles containing colchicine or a colchicine analogue: effects on restenosis and implications for catheter-based drug delivery. J Am Coll Cardiol 1995; 26(6): 1549-1557.
103. Margolin L, Fishbein I, Banai S, et al. Metalloproteinase inhibitor attenuates neointima formation and constrictive remodeling after angioplasty in rats: augmentative effect of alpha(v)beta(3) receptor blockade. Atherosclerosis 2002; 163(2):269-277.
104. van Beusekom HM, Post MJ, Whelan DM, de Smet BJ, Duncker DJ, van der Giessen WJ. Metalloproteinase inhibition by batimastat does not reduce neointimal thickening in stented atherosclerotic porcine femoral arteries. Cardiovasc Radiat Med 2003; 4(4):186-191.
105. Wu CH, Pan JS, Chang WC, Hung JS, Mao SJ. The molecular mechanism of actinomycin D in preventing neointimal formation in rat carotid arteries after balloon injury. J Biomed Sci 2005; 12(3):503-512.
106. Suzuki T, Kopia G, Hayashi S, et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001; 104(10):1188-1193.